196 related articles for article (PubMed ID: 37423227)
1. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C; Finneran L; Roe J; Sydenham MA; Beasley M; Bhide S; Boon C; Cook A; De Winton E; Emson M; Foran B; Frogley R; Petkar I; Pettit L; Rooney K; Roques T; Srinivasan D; Tyler J; Hall E;
Lancet Oncol; 2023 Aug; 24(8):868-880. PubMed ID: 37423227
[TBL] [Abstract][Full Text] [Related]
2. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Nichols AC; Theurer J; Prisman E; Read N; Berthelet E; Tran E; Fung K; de Almeida JR; Bayley A; Goldstein DP; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Winquist E; Hammond JA; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Chen J; Corsten M; Johnson-Obaseki S; Eapen L; Odell M; Parker C; Wehrli B; Kwan K; Palma DA
Lancet Oncol; 2019 Oct; 20(10):1349-1359. PubMed ID: 31416685
[TBL] [Abstract][Full Text] [Related]
4. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
[TBL] [Abstract][Full Text] [Related]
5. Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.
Batham S; Gupta S; Ghosh A; Gupta IJ; Johny D; Srivastava S; Singh N; Bhatt M; Gupta R; Bhosale VV; Negi M
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3697-3704. PubMed ID: 38019227
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Achieving Dose Constraints for Dysphagia Aspiration-Related Structures and Its Clinical Significance in Intensity-Modulated Radiotherapy Planning of Head and Neck Cancer.
Agarwal K; Kumar P; S N; Kumar P; Garg A; Nigam J; N S S
Cureus; 2024 Feb; 16(2):e53769. PubMed ID: 38465172
[TBL] [Abstract][Full Text] [Related]
7. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?
Eisbruch A; Schwartz M; Rasch C; Vineberg K; Damen E; Van As CJ; Marsh R; Pameijer FA; Balm AJ
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1425-39. PubMed ID: 15590174
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Dosimetric Parameters in Dysphagia Aspiration-Related Structures and Clinical Correlation in Head and Neck Cancer Patients Treated With Radiotherapy.
Upadhyay P; Kumar P; Chauhan AK; Kumar P; Nigam J; S N
Cureus; 2022 Jul; 14(7):e26765. PubMed ID: 35967135
[TBL] [Abstract][Full Text] [Related]
9. Dysphagia-optimised Intensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is Anyone Going to Swallow it?
Petkar I; Bhide S; Newbold K; Harrington K; Nutting C
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):e110-e118. PubMed ID: 28242166
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Sherman EJ; Harris J; Bible KC; Xia P; Ghossein RA; Chung CH; Riaz N; Gunn GB; Foote RL; Yom SS; Wong SJ; Koyfman SA; Dzeda MF; Clump DA; Khan SA; Shah MH; Redmond K; Torres-Saavedra PA; Le QT; Lee NY
Lancet Oncol; 2023 Feb; 24(2):175-186. PubMed ID: 36681089
[TBL] [Abstract][Full Text] [Related]
12. Impact of Radiation on Dysphagia-Related Structures: A Dosimetric and Clinical Comparative Analysis of Three-Dimensional Conformal Radiotherapy (3D-CRT) and Intensity-Modulated Radiation Therapy (IMRT) Techniques in Patients With Head and Neck Cancer.
Manam S; Teja R; Pb AR; Azharuddin SK
Cureus; 2024 Apr; 16(4):e58276. PubMed ID: 38752101
[TBL] [Abstract][Full Text] [Related]
13. Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer.
Bhide SA; Gulliford S; Kazi R; El-Hariry I; Newbold K; Harrington KJ; Nutting CM
Radiother Oncol; 2009 Dec; 93(3):539-44. PubMed ID: 19883951
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the Effect of Radiotherapy Dose on Chewing and Swallowing Structures in Head and Neck Cancer Patients Treated with Concomitant Chemoradiotherapy.
Baştuğ Dumbak A; Esen Aydınlı F; Yazıcı G; İncebay Ö; Yıldız Z; Yüce D; Süslü N; Kuşçu O; Kulak Kayıkcı ME
Dysphagia; 2022 Dec; 37(6):1400-1413. PubMed ID: 35075541
[TBL] [Abstract][Full Text] [Related]
15. Toxicities and clinical outcome of adjuvant dysphagia optimized versus standard intensity-modulated radiotherapy for post-operative oral cavity cancers: A prospective comparative study.
Patni A; Rastogi M; Gandhi AK; Mishra VK; Srivastava AK; Sharma V; Agarwal A; Khurana R; Hadi R; Sapru S; Mishra SP
Head Neck; 2023 Dec; 45(12):3119-3128. PubMed ID: 37814926
[TBL] [Abstract][Full Text] [Related]
16. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
17. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.
Goepfert RP; Lewin JS; Barrow MP; Fuller CD; Lai SY; Song J; Hobbs BP; Gunn GB; Beadle BM; Rosenthal DI; Garden AS; Kies MS; Papadimitrakopoulou VA; Schwartz DL; Hutcheson KA
Laryngoscope; 2017 Apr; 127(4):842-848. PubMed ID: 27440393
[TBL] [Abstract][Full Text] [Related]
18. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
19. Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma.
Mogadas S; Busch CJ; Pflug C; Hanken H; Krüll A; Petersen C; Tribius S
Strahlenther Onkol; 2020 Jun; 196(6):522-529. PubMed ID: 32006068
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia?
Roe JW; Drinnan MJ; Carding PN; Harrington KJ; Nutting CM
Oral Oncol; 2014 Dec; 50(12):1182-7. PubMed ID: 25448227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
